Celldex Appoints Elizabeth Crowley as Chief Product Development Officer
11 August 2016 - 10:01PM
Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the
Company has promoted Elizabeth Crowley to the newly created
position of Senior Vice President, Chief Product Development
Officer. Ms. Crowley was previously Senior Vice President of
Product Development of Celldex and brings almost 25 years of
industry experience where she was responsible for leading the
execution of multiple successful drug development programs.
“Celldex was founded on the belief that combination regimens
designed to unlock the power of the immune system would deliver the
greatest benefit to the largest population of patients,” said
Anthony Marucci, Co-founder, President and Chief Executive Officer
of Celldex Therapeutics. “This newly created position is a direct
response to the future of portfolio planning and drug development
in the immuno-oncology field where we believe multi-drug
combination regimens will become the norm and the development
programs to explore these opportunities will become increasingly
complex. Beth’s deep, oncology-focused experience in strategic
planning, portfolio management and implementation have played a
critical role in building the depth and breadth of our pipeline to
date and an exceptional development operations team here at
Celldex. We look forward to her continued expertise in this
expanded leadership role.”
"Celldex has thoughtfully seeded a pipeline with individual
product candidates that uniquely manipulate the immune system at
key points,” said Ms. Crowley. “With successful proof of concept
work achieved, we have now entered the next phase of development
and are extensively exploring multi-drug combination regimens. I
look forward to working closely with my Celldex colleagues across
the organization as we expand this approach in our ongoing efforts
to improve outcomes for patients and their families.”
Ms. Crowley joined Celldex in 2009 as Vice President, Clinical
Development. Prior to that, she held several senior level roles at
CuraGen Corporation, most recently serving as the Vice President of
Development Operations, responsible for strategic and operational
development activities of the oncology and oncology supportive care
portfolio, regulatory affairs, clinical operations and data
management. Ms. Crowley started her career at Bayer Corporation in
1992, holding various positions providing leadership of clinical
research and project management prior to completing her tenure
there as the Director of Global Study Audit Management, assuring
the highest standards for program execution. Ms. Crowley received
her BS in Chemistry with a concentration in Business from Boston
College.
About Celldex Therapeutics, Inc.
Celldex is developing targeted therapeutics to address
devastating diseases for which available treatments are inadequate.
Our pipeline is built from a proprietary portfolio of antibodies
and immunomodulators used alone and in strategic combinations to
create novel, disease-specific therapies that induce, enhance or
suppress the body's immune response. Visit www.celldex.com.
Forward Looking Statement
This release contains "forward-looking statements" made pursuant
to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995, including those related to the Company's
strategic focus and the future development and commercialization
(by Celldex and others) of glembatumumab vedotin ("glemba";
CDX-011), varlilumab (“varli”; CDX-1127) and other products and our
goals for 2016. Forward-looking statements reflect management's
current knowledge, assumptions, judgment and expectations regarding
future performance or events. Although management believes that the
expectations reflected in such statements are reasonable, they give
no assurance that such expectations will prove to be correct or
that those goals will be achieved, and you should be aware that
actual results could differ materially from those contained in the
forward-looking statements. Forward-looking statements are subject
to a number of risks and uncertainties, including, but not limited
to, our ability to successfully complete research and further
development and commercialization of glembatumumab vedotin and
other drug candidates; our ability to obtain additional capital to
meet our long-term liquidity needs on acceptable terms, or at all,
including the additional capital which will be necessary to
complete the clinical trials that we have initiated or plan to
initiate; the uncertainties inherent in clinical testing and
accruing patients for clinical trials; our limited experience in
bringing programs through Phase 3 clinical trials; our ability to
manage and successfully complete multiple clinical trials and the
research and development efforts for our multiple products at
varying stages of development; the availability, cost, delivery and
quality of clinical and commercial grade materials produced by our
own manufacturing facility or supplied by contract manufacturers,
who may be our sole source of supply; the timing, cost and
uncertainty of obtaining regulatory approvals; our ability to
maintain and derive benefit from the Fast Track designation for
glembatumumab vedotin which does not change the standards for
regulatory approval or guarantee regulatory approval on an
expedited basis, or at all; the failure of the market for the
Company's programs to continue to develop; our ability to protect
the Company's intellectual property; the loss of any executive
officers or key personnel or consultants; competition; changes in
the regulatory landscape or the imposition of regulations that
affect the Company's products; and other factors listed under "Risk
Factors" in our annual report on Form 10-K and quarterly reports on
Form 10-Q.
All forward-looking statements are expressly qualified in their
entirety by this cautionary notice. You are cautioned not to place
undue reliance on any forward-looking statements, which speak only
as of the date of this release. We have no obligation, and
expressly disclaim any obligation, to update, revise or correct any
of the forward-looking statements, whether as a result of new
information, future events or otherwise.
Company Contact
Sarah Cavanaugh
Vice President of Investor Relations & Corp Communications
Celldex Therapeutics, Inc.
(781) 433-3161
scavanaugh@celldex.com
Charles Liles
Associate Director of Investor Relations & Corp Communications
Celldex Therapeutics, Inc.
(781) 433-3107
cliles@celldex.com
Media Inquiries
Dan Budwick
Pure Communications, Inc.
(973) 271-6085
dan@purecommunicationsinc.com
Celldex Therapeutics (NASDAQ:CLDX)
Historical Stock Chart
From Apr 2024 to May 2024
Celldex Therapeutics (NASDAQ:CLDX)
Historical Stock Chart
From May 2023 to May 2024